Our technology originated at University of British Columbia, Department of Infectious Disease in Vancouver, Canada. Phase 1 trials were conducted in healthy volunteers in Canada. Results of these studies were published in the Cystic Fibrosis Journal.

In 2011, Advanced Inhalation Therapies (AIT) was formed and the company developed a proprietary technology to safely deliver Nitric Oxide gas to patients with bronchiolitis and cystic fibrosis.

Over the next few years, the company conducted several Phase 2 trials. In each study, we did not observe any Serious Adverse Events (SAEs), however, improvement in oxygenation, significant reduction of time to discharge and reduction of bacterial loads were observed.

In 2017 AIT became a publicly traded company and the AIT team is now preparing for pivotal registration trials.